

2023 Complex General Surgical Oncology Continuous Certification Assessment

All References



www.absurgery.org

Below you will find the topics and their accompanying references for the 2023 Complex General Surgical Oncology Continuous Certification Assessment. **Diplomates are neither required nor expected to read all of these references before or during the completion of the assessment.** The Key References are marked with a yellow star ★ below.

Please note that the American Board of Surgery (ABS) provides as many open-access articles to our Candidates as possible. While you are completing your assessment, Key References will have a direct link to a full-text article or an article PDF purchased by the ABS in the exam platform. Due to limited permissions, we cannot provide links to full-text articles or article PDFs on this Reference Document, as it is not hosted on a secure browser. Article links on this document will take you to the article page on PubMed. We cannot guarantee that all article links will be open access on PubMed. **To view the full-text Key References prior to beginning your assessment, please log into the ABS surgeon portal and find the “My Continuous Certification” page. Under the “Assessments” tab, click on “Reference Documents”.**

The screenshot shows a dashboard for 'My Continuous Certification'. At the top, there is a blue header with a gear icon, the text 'My Continuous Certification', and a 'MORE INFO' link. Below the header, there are two tabs: 'Ongoing Requirements' with a count of 0, and 'Assessments (Examinations)' with a count of 1. The main content area is titled 'Register for Surgery Assessment' and contains a table with four rows, each with a dropdown arrow on the left and a status on the right.

Task	Status
Reference Documents	
Provide Digital Signature	NOT YET COMPLETED ○
Launch Assessment	NOT YET AVAILABLE ○
View Performance Report	NOT YET AVAILABLE ○

Adrenal

- Iacobone M, Citton M, Scarpa M, Viel G, Boscaro M, Nitti D. Systematic review of surgical treatment of subclinical Cushing's syndrome. *Br J Surg*. 2015;102(4):318-330. doi:10.1002/bjs.9742 [PMID: [25640696](#)]
- ★ Kebebew E. Adrenal Incidentaloma. *N Engl J Med*. 2021;384(16):1542-1551. doi:10.1056/NEJMcp2031112 [PMID: [33882207](#)]
- Lee JM, Kim MK, Ko SH, et al. Clinical guidelines for the management of adrenal incidentaloma. *Endocrinol Metab (Seoul)*. 2017;32(2):200-218. doi:10.3803/EnM.2017.32.2.200 [PMID: [28685511](#)]
- Park J, De Luca A, Dutton H, Malcolm JC, Doyle MA. Cardiovascular outcomes in autonomous cortisol secretion and nonfunctioning adrenal adenoma: a systematic review. *J Endocr Soc*. 2019;3(5):996-1008. doi:10.1210/js.2019-00090 [PMID: [31065617](#)]
- ★ Yip L, Duh QY, Wachtel H, et al. American Association of Endocrine Surgeons guidelines for adrenalectomy: executive summary. *JAMA Surg*. 2022;157(10):870-877. doi:10.1001/jamasurg.2022.3544 [PMID: [35976622](#)]

Adrenal- Secondary Malignancy to the Adrenal Gland

- Gao XL, Zhang KW, Tang MB, Zhang KJ, Fang LN, Liu W. Pooled analysis for surgical treatment for isolated adrenal metastasis and non-small cell lung cancer. *Interact Cardiovasc Thorac Surg*. 2017;24(1):1-7. doi:10.1093/icvts/ivw321 [PMID: [27664424](#)]
- ★ Jasper K, Stiles B, McDonald F, Palma DA. Practical management of oligometastatic non-small-cell lung cancer. *J Clin Oncol*. 2022;40(6):635-641. doi:10.1200/JCO.21.01719 [PMID: [34985915](#)]
- Tomasini P, Garcia ME, Greillier L, Paladino C, Sebag F, Barlesi F. Adrenal surgery for oligometastatic tumors improves survival in selected cases. *J Visc Surg*. 2017;154(2):87-91. doi:10.1016/j.jvisurg.2016.08.007 [PMID: [27642061](#)]
- van Vliet C, Dickhoff C, Bahce I, et al. Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period. *Radiother Oncol*. 2022;170:165-168. doi:10.1016/j.radonc.2022.02.023 [PMID: [35219801](#)]

Anal Canal Carcinoma

- ★ Stewart DB, Gaertner WB, Glasgow SC, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for anal squamous cell cancers (revised 2018). *Dis Colon Rectum*. 2018;61(7):755-774. doi:10.1097/DCR.0000000000001114 [PMID: [29878949](#)]

Biliary Tract Cancer

- Edeline J, Benabdelghani M, Bertaut A, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. *J Clin Oncol*. 2019;37(8):658-667. doi:10.1200/JCO.18.00050 [PMID: [30707660](#)]
- ★ Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. *Lancet Oncol*. 2019;20(5):663-673. doi:10.1016/S1470-2045(18)30915-X [PMID: [30922733](#)]

Breast- Atypical Ductal Hyperplasia

- American Society of Breast Surgeons. Consensus Guideline on Concordance Assessment of Image-Guided Breast Biopsies and Management of Borderline or High-Risk Lesions. American Society of Breast Surgeons. 2018. Accessed May 3, 2023. <https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Concordance-Assessment-of-Image-Guided-Breast-Biopsies.pdf?v2>
- American Society of Breast Surgeons. Consensus Guideline on Diagnostic and Screening Magnetic Resonance Imaging of the Breast. American Society of Breast Surgeons. 2018. Accessed May 3, 2023. <https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Diagnostic-and-Screening-Magnetic-Resonance-Imaging-of-the-Breast.pdf>
- ★ Bong TSH, Tan JKT, Ho JTS, et al. Atypical ductal hyperplasia of the breast on core needle biopsy: risk of malignant upgrade on surgical excision. *J Breast Cancer*. 2022;25(1):37-48. doi:10.4048/jbc.2022.25.e7 [PMID: [35199500](#)]
- Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. *Lancet Oncol*. 2015;16(1):67-75. doi:10.1016/S1470-2045(14)71171-4 [PMID: [25497694](#)]

Breast- Mondor Disease

- ★ Catania S, Zurrida S, Veronesi P, Galimberti V, Bono A, Pluchinotta A. Mondor's disease and breast cancer. *Cancer*. 1992;69(9):2267-2270. doi:10.1002/1097-0142(19920501)69:9<2267::aid-cnrcr2820690910>3.0.co;2-u [PMID: [1562972](#)]

Breast- Paget Disease

- Kollmorgen DR, Varanasi JS, Edge SB, Carson WE 3rd. Paget's disease of the breast: a 33-year experience. *J Am Coll Surg*. 1998;187(2):171-177. doi:10.1016/s1072-7515(98)00143-4 [PMID: [9704964](#)]
- ★ NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.4.2023. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 15, 2023. To view the most recent and complete version of the guideline, go online to [NCCN.org](#). *Requires login to NCCN; NCCN accounts are free to create. Please search for the appropriate Guidelines under Guidelines > Treatment by Cancer Type/Detection, Prevention, and Risk Reduction.*
- Ortiz-Pagan S, Cunto-Amesty G, Narayan S, et al. Effect of Paget's disease on survival in breast cancer: an exploratory study. *Arch Surg*. 2011;146(11):1267-1270. doi:10.1001/archsurg.2011.278 [PMID: [22106318](#)]

Breast- Survivorship

- Dieli-Conwright CM, Wong L, Walianny S, Bernstein L, Salehian B, Mortimer JE. An observational study to examine changes in metabolic syndrome components in patients with breast cancer receiving neoadjuvant or adjuvant chemotherapy. *Cancer*. 2016;122(17):2646-2653. doi:10.1002/cncr.30104 [PMID: [27219902](#)]
- McLaughlin SA, Brunelle CL, Taghian A. Breast cancer-related lymphedema: risk factors, screening, management, and the impact of locoregional treatment. *J Clin Oncol*. 2020;38(20):2341-2350. doi:10.1200/JCO.19.02896 [PMID: [32442064](#)]
- ★ Runowicz CD, Leach CR, Henry NL, et al. American Cancer Society/American Society of Clinical Oncology breast cancer survivorship care guideline. *CA Cancer J Clin*. 2016;66(1):43-73. doi:10.3322/caac.21319 [PMID: [26641959](#)]

Colorectal Cancer- Liver Metastasis

- Buisman FE, Galjart B, van der Stok EP, et al. Recurrence patterns after resection of colorectal liver metastasis are modified by perioperative systemic chemotherapy. *World J Surg*. 2020;44(3):876-886. doi:10.1007/s00268-019-05121-9 [PMID: [31410513](#)]

- Ignatavicius P, Oberkofler CE, Chapman WC, et al. Choices of therapeutic strategies for colorectal liver metastases among expert liver surgeons: a throw of the dice?. *Ann Surg*. 2020;272(5):715-722. doi:10.1097/SLA.0000000000004331 [PMID: [32833764](#)]
- ★ Viganò L, Procopio F, Cimino MM, et al. Is tumor detachment from vascular structures equivalent to R0 resection in surgery for colorectal liver metastases? an observational cohort. *Ann Surg Oncol*. 2016;23(4):1352-1360. doi:10.1245/s10434-015-5009-y [PMID: [26714946](#)]
- Wasan HS, Gibbs P, Sharma NK, et al. First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. *Lancet Oncol*. 2017;18(9):1159-1171. doi:10.1016/S1470-2045(17)30457-6 [PMID: [28781171](#)]

Colorectal Cancer- Microsatellite High

- ★ André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. *N Engl J Med*. 2020;383(23):2207-2218. doi:10.1056/NEJMoa2017699 [PMID: [33264544](#)]
- ★ NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed May 3, 2023. To view the most recent and complete version of the guideline, go online to [NCCN.org](#). Requires login to NCCN; NCCN accounts are free to create. Please search for the appropriate Guidelines under Guidelines > Treatment by Cancer Type/Detection, Prevention, and Risk Reduction.
- ★ Vogel JD, Felder SI, Bhamra AR, et al. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the management of colon cancer. *Dis Colon Rectum*. 2022;65(2):148-177. doi:10.1097/DCR.0000000000002323 [PMID: [34775402](#)]

Colorectal Cancer- Radiation Proctitis

- ★ Paquette IM, Vogel JD, Abbas MA, Feingold DL, Steele SR; Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons clinical practice guidelines for the treatment of chronic radiation proctitis. *Dis Colon Rectum*. 2018;61(10):1135-1140. doi:10.1097/DCR.0000000000001209 [PMID: [30192320](#)]
- Sharma B, Gupta M, Sharma R, et al. Four percent formalin application for the management of radiation proctitis in carcinoma cervix patients: an effective, safe, and

economical practice. *J Cancer Res Ther.* 2019;15(1):92-95.
doi:10.4103/jcrt.JCRT_393_17 [PMID: [30880761](#)]

Colorectal Cancer- Rectal Adenocarcinoma

- Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. *Lancet Oncol.* 2021;22(1):29-42. doi:10.1016/S1470-2045(20)30555-6 [PMID: [33301740](#)]
- ★ Conrad C, Vauthey JN, Masayuki O, et al. Individualized treatment sequencing selection contributes to optimized survival in patients with rectal cancer and synchronous liver metastases. *Ann Surg Oncol.* 2017;24(13):3857-3864. doi:10.1245/s10434-017-6089-7 [PMID: [28929463](#)]
- Conroy T, Bosset JF, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol.* 2021;22(5):702-715. doi:10.1016/S1470-2045(21)00079-6 [PMID: [33862000](#)]
- ★ Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. *J Clin Oncol.* 2022;40(23):2546-2556. doi:10.1200/JCO.22.00032 [PMID: [35483010](#)]

Cutaneous Squamous Cell Carcinoma

- ★ Gross ND, Miller DM, Khushalani NI, et al. Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma. *N Engl J Med.* 2022;387(17):1557-1568. doi:10.1056/NEJMoa2209813 [PMID: [36094839](#)]

Disparities in Clinical Trials

- ★ Adams-Campbell LL, Ahaghotu C, Gaskins M, et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. *J Clin Oncol.* 2004;22(4):730-734. doi:10.1200/JCO.2004.03.160 [PMID: [14966098](#)]
- Diehl KM, Green EM, Weinberg A, et al. Features associated with successful recruitment of diverse patients onto cancer clinical trials: report from the American College of Surgeons Oncology Group. *Ann Surg Oncol.* 2011;18(13):3544-3550. doi:10.1245/s10434-011-1818-9 [PMID: [21681382](#)]

Esophageal Cancer

- Defize IL, Goense L, Borggreve AS, et al. Risk factors for tumor positive resection margins after neoadjuvant chemoradiotherapy for esophageal cancer: results from the Dutch upper GI cancer audit: a nationwide population-based study. *Ann Surg*. 2021;10.1097/SLA.0000000000005112. doi:10.1097/SLA.0000000000005112 [PMID: [34334634](#)]
- ★ Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. *N Engl J Med*. 2021;384(13):1191-1203. doi:10.1056/NEJMoa2032125 [PMID: [33789008](#)]
- Ma LX, Espin-Garcia O, Lim CH, et al. Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastric and esophageal cancers. *J Gastrointest Oncol*. 2020;11(2):356-365. doi:10.21037/jgo.2020.03.03 [PMID: [32399276](#)]

Gallbladder Cancer

- ★ Patkar S, Gundavda K, Chaudhari V, et al. Utility and limitations of intraoperative frozen section diagnosis to determine optimal surgical strategy in suspected gallbladder malignancy. *HPB (Oxford)*. 2023;25(3):330-338. doi:10.1016/j.hpb.2022.12.003 [PMID: [36586775](#)]
- Pehlivanoglu B, Akkas G, Memis B, et al. Reappraisal of T1b gallbladder cancer (GBC): clinicopathologic analysis of 473 in situ and invasive GBCs and critical review of the literature highlights its rarity, and that it has a very good prognosis. *Virchows Arch*. 2023;482(2):311-323. doi:10.1007/s00428-022-03482-6 [PMID: [36580138](#)]

Ganglioneuroma

- ★ Noh S, Nessim C, Keung EZ, et al. Retrospective analysis of retroperitoneal-abdominal-pelvic ganglioneuromas: an international study by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. *Ann Surg*. 2022;10.1097/SLA.0000000000005625. doi:10.1097/SLA.0000000000005625 [PMID: [35866666](#)]

Gastric Cancer

- ★ Blair VR, McLeod M, Carneiro F, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. *Lancet Oncol*. 2020;21(8):e386-e397. doi:10.1016/S1470-2045(20)30219-9 [PMID: [32758476](#)]

- Lee CYC, Olivier A, Honing J, et al. Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study. *Lancet Oncol.* 2023;24(1):107-116. doi:10.1016/S1470-2045(22)00700-8 [PMID: [36509094](#)]

Gastrointestinal Stromal Tumors

- Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFR α mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. *Eur J Cancer.* 2004;40(5):689-695. doi:10.1016/j.ejca.2003.11.025 [PMID: [15010069](#)]
- ★ Nishida T, Cho H, Hirota S, et al. Clinicopathological features and prognosis of primary GISTs with tumor rupture in the real world. *Ann Surg Oncol.* 2018;25(7):1961-1969. doi:10.1245/s10434-018-6505-7 [PMID: [29752602](#)]
- Rutkowski P, Nowecki ZI, Michej W, et al. Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor. *Ann Surg Oncol.* 2007;14(7):2018-2027. doi:10.1245/s10434-007-9377-9 [PMID: [17473953](#)]

Gastrointestinal Stromal Tumors- Succinate Dehydrogenase-Deficient

- Else T, Greenberg S, Fishbein L. Hereditary paraganglioma-pheochromocytoma syndromes. In: Adam MP, Mirzaa GM, Pagon RA, et al., eds. *GeneReviews*. University of Washington; 2008.
- Neppala P, Banerjee S, Fanta PT, et al. Current management of succinate dehydrogenase-deficient gastrointestinal stromal tumors. *Cancer Metastasis Rev.* 2019;38(3):525-535. doi:10.1007/s10555-019-09818-0 [PMID: [31773431](#)]
- ★ Saie C, Buffet A, Abeillon J, et al. Screening of a large cohort of asymptomatic SDHx mutation carriers in routine practice. *J Clin Endocrinol Metab.* 2021;106(3):e1301-e1315. doi:10.1210/clinem/dgaa888 [PMID: [33247927](#)]
- Wong MY, Andrews KA, Challis BG, et al. Clinical practice guidance: surveillance for pheochromocytoma and paraganglioma in paediatric succinate dehydrogenase gene mutation carriers. *Clin Endocrinol (Oxf).* 2019;90(4):499-505. doi:10.1111/cen.13926 [PMID: [30589099](#)]

Hepatocellular Adenoma

- European Association for the Study of the Liver (EASL). EASL clinical practice guidelines on the management of benign liver tumours. *J Hepatol*. 2016;65(2):386-398. doi:10.1016/j.jhep.2016.04.001 [PMID: [27085809](#)]
- ★ van Rosmalen BV, Furumaya A, Klompenhouwer AJ, et al. Hepatocellular adenoma in men: a nationwide assessment of pathology and correlation with clinical course. *Liver Int*. 2021;41(10):2474-2484. doi:10.1111/liv.14989 [PMID: [34155783](#)]
- Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. *Hepatology*. 2006;43(3):515-524. doi:10.1002/hep.21068 [PMID: [16496320](#)]

Hypercalcemia

- ★ Carroll R, Matfin G. Endocrine and metabolic emergencies: hypercalcaemia. *Ther Adv Endocrinol Metab*. 2010;1(5):225-234. doi:10.1177/2042018810390260 [PMID: [23148166](#)]

Hypercalcemia- Secondary Hyperparathyroidism

- ★ Dream S, Kuo LE, Kuo JH, et al. The American Association of Endocrine Surgeons guidelines for the definitive surgical management of secondary and tertiary renal hyperparathyroidism. *Ann Surg*. 2022;276(3):e141-e176. doi:10.1097/SLA.0000000000005522 [PMID: [35848728](#)]
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). *Kidney Int Suppl (2011)*. 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001 [PMID: [30675420](#)]

Melanoma- Anal

- Pessaux P, Pocard M, Elias D, et al. Surgical management of primary anorectal melanoma. *Br J Surg*. 2004;91(9):1183-1187. doi:10.1002/bjs.4592 [PMID: [15449271](#)]
- ★ Roy AC, Wattchow D, Astill D, et al. Uncommon anal neoplasms. *Surg Oncol Clin N Am*. 2017;26(1):143-161. doi:10.1016/j.soc.2016.07.009 [PMID: [27889033](#)]

Melanoma- Cutaneous

- Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern

Cooperative Oncology Group Trial EST 1684. *J Clin Oncol*. 1996;14(1):7-17. doi:10.1200/JCO.1996.14.1.7 [PMID: [8558223](#)]

Melanoma- Desmoplastic

- Eroglu Z, Zaretsky JM, Lieskovan SH, et al. High response rate to PD-1 blockade in desmoplastic melanomas. *Nature*. 2018;553(7688):347-350. doi:10.1038/nature25187 [PMID: [29320474](#)]
- Han D, Zager JS, Yu D, et al. Desmoplastic melanoma: is there a role for sentinel lymph node biopsy?. *Ann Surg Oncol*. 2013;20(7):2345-2351. doi:10.1245/s10434-013-2883-z [PMID: [23389470](#)]
- Kendra K, Bellasea S, Eroglu Z, et al. High response rate with single agent anti-PD-1 in patients with metastatic desmoplastic melanoma. *Cancer Res*. 2023;83(suppl 8):CT009. doi:10.1158/1538-7445.AM2023-CT009
- ★ Kendra KL, Moon J, Eroglu Z, et al. Neoadjuvant PD-1 blockade in patients with resectable desmoplastic melanoma (SWOG 1512). *J Clin Oncol*. 2022;40(suppl 16):9502. doi:10.1200/JCO.2022.40.16_suppl.9502
- Livestro DP, Muzikansky A, Kaine EM, et al. Biology of desmoplastic melanoma: a case-control comparison with other melanomas. *J Clin Oncol*. 2005;23(27):6739-6746. doi:10.1200/JCO.2005.04.515 [PMID: [16170181](#)]

Melanoma- Immunotherapy

- ★ Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. *Lancet*. 2022;399(10336):1718-1729. doi:10.1016/S0140-6736(22)00562-1 [PMID: [35367007](#)]
- ★ Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. *N Engl J Med*. 2023;388(9):813-823. doi:10.1056/NEJMoa2211437 [PMID: [36856617](#)]

Melanoma- Sentinel Lymph Node Biopsy

- ★ Lo SN, Ma J, Scolyer RA, et al. Improved risk prediction calculator for sentinel node positivity in patients with melanoma: the Melanoma Institute Australia nomogram. *J Clin Oncol*. 2020;38(24):2719-2727. doi:10.1200/JCO.19.02362 [PMID: [32530761](#)]

Pancreatic Neuroendocrine Neoplasms

- ★ Magi L, Marasco M, Rinzivillo M, Faggiano A, Panzuto F. Management of functional pancreatic neuroendocrine neoplasms. *Curr Treat Options Oncol*. 2023;10.1007/s11864-023-01085-0. doi:10.1007/s11864-023-01085-0 [PMID: [37103745](#)]

Pheochromocytoma/Paraganglioma

- Karasek D, Fryszak Z, Pacak K. Genetic testing for pheochromocytoma. *Curr Hypertens Rep*. 2010;12(6):456-464. doi:10.1007/s11906-010-0151-1 [PMID: [20938758](#)]
- Muth A, Crona J, Gimm O, et al. Genetic testing and surveillance guidelines in hereditary pheochromocytoma and paraganglioma. *J Intern Med*. 2019;285(2):187-204. doi:10.1111/joim.12869 [PMID: [30536464](#)]
- ★ Yip L, Duh QY, Wachtel H, et al. American Association of Endocrine Surgeons guidelines for adrenalectomy: executive summary. *JAMA Surg*. 2022;157(10):870-877. doi:10.1001/jamasurg.2022.3544 [PMID: [35976622](#)]

Sarcoma- Angiosarcoma of the Breast

- ★ Arora TK, Terracina KP, Soong J, Idowu MO, Takabe K. Primary and secondary angiosarcoma of the breast. *Gland Surg*. 2014;3(1):28-34. doi:10.3978/j.issn.2227-684X.2013.12.03 [PMID: [25083491](#)]
- Depla AL, Scharloo-Karels CH, de Jong MAA, et al. Treatment and prognostic factors of radiation-associated angiosarcoma (RAAS) after primary breast cancer: a systematic review. *Eur J Cancer*. 2014;50(10):1779-1788. doi:10.1016/j.ejca.2014.03.002 [PMID: [24731859](#)]
- Gutkin PM, Ganjoo KN, Lohman M, et al. Angiosarcoma of the breast: management and outcomes. *Am J Clin Oncol*. 2020;43(11):820-825. doi:10.1097/COC.0000000000000753 [PMID: [32889893](#)]

Sarcoma- Liposarcoma

- Callegaro D, Barretta F, Swallow CJ, et al. Longitudinal prognostication in retroperitoneal sarcoma survivors: Development and external validation of two dynamic nomograms. *Eur J Cancer*. 2021;157:291-300. doi:10.1016/j.ejca.2021.08.008 [PMID: [34555648](#)]

- Nessim C, Raut CP, Callegaro D, et al. Analysis of differentiation changes and outcomes at time of first recurrence of retroperitoneal liposarcoma by Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). *Ann Surg Oncol*. 2021;28(12):7854-7863. doi:10.1245/s10434-021-10024-y [PMID: [33907921](#)]
- ★ Trans-Atlantic RPS Working Group. Management of recurrent retroperitoneal sarcoma (RPS) in the adult: a consensus approach from the trans-atlantic RPS Working Group. *Ann Surg Oncol*. 2016;23(11):3531-3540. doi:10.1245/s10434-016-5336-7 [PMID: [27480354](#)]

Thyroid Cancer- Anaplastic

- ★ Bible KC, Kebebew E, Brierley J, et al. 2021 American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. *Thyroid*. 2021;31(3):337-386. doi:10.1089/thy.2020.0944 [PMID: [33728999](#)]
- Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. *Ann Oncol*. 2022;33(4):406-415. doi:10.1016/j.annonc.2021.12.014 [PMID: [35026411](#)]

Thyroid Cancer- Pregnancy

- ★ Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid*. 2017;27(3):315-389. doi:10.1089/thy.2016.0457 [PMID: [28056690](#)]
- Uruno T, Shibuya H, Kitagawa W, Nagahama M, Sugino K, Ito K. Optimal timing of surgery for differentiated thyroid cancer in pregnant women. *World J Surg*. 2014;38(3):704-708. doi:10.1007/s00268-013-2334-9. [PMID: [24248429](#)]

Understanding Quality Metrics

- Fischer CP, Hu QL, Wescott AB, Maggard-Gibbons M, Hoyt DB, Ko CY. Evidence review for the American College of Surgeons quality verification part II: processes for reliable quality improvement. *J Am Coll Surg*. 2021;233(2):294-311.e1. doi:10.1016/j.jamcollsurg.2021.03.028 [PMID: [33940183](#)]
- ★ Kao LS, Dimick JB, Porter GA; Evidence-Based Reviews in Surgery Group. How do administrative data compare with a clinical registry for identifying 30-day postoperative complications?. *J Am Coll Surg*. 2014;219(6):1187-1191. doi:10.1016/j.jamcollsurg.2014.09.002 [PMID: [25458238](#)]